{"groups":[{"description":"Dose Level 0: Carfilzomib IV (20 mg/m\\^2) D1\\&D2 of C1 and carfilzomib IV (27 mg/m\\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (27 mg/m\\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (27 mg/m\\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\\^2)D8 C1-6.","id":"FG000","title":"Phase I - Part 1 Dose Level 0 (Carfilzomib 20/27 mg/m^2)"},{"description":"Dose Level 1: Carfilzomib IV (20 mg/m\\^2) D1\\&D2 of C1 and carfilzomib IV (36 mg/m\\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (36 mg/m\\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (36 mg/m\\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\\^2)D8 C1-6.","id":"FG001","title":"Phase I - Part 1 Dose Level 1 (Carfilzomib 20/36 mg/m^2)"},{"description":"Dose Level 2: Carfilzomib IV (20 mg/m\\^2) D1\\&D2 of C1 and carfilzomib IV (45 mg/m\\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (45 mg/m\\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (45 mg/m\\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\\^2)D8 C1-6.","id":"FG002","title":"Phase I - Part 1 Dose Level 2 (Carfilzomib 20/45 mg/m^2)"},{"description":"Dose Level 3: Carfilzomib IV (20 mg/m\\^2) D1\\&D2 of C1 and carfilzomib IV (56 mg/m\\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (56 mg/m\\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (56 mg/m\\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\\^2)D8 C1-6.","id":"FG003","title":"Phase I - Part 1 Dose Level 3 (Carfilzomib 20/56 mg/^2)"},{"description":"Cohort 0: Carfilzomib IV (56 mg/\\^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m\\^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m\\^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.","id":"FG004","title":"Phase I -Part 2 Cohort 0 (Carfilzomib 56 mg/m^2+Dexamethasone)"},{"description":"Carfilzomib IV (56 mg/\\^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m\\^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m\\^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.","id":"FG005","title":"Phase 2 (Carfilzomib 56 mg/m^2+ Dexamethasone)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"7"},{"groupId":"FG005","numSubjects":"17"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"7"},{"groupId":"FG005","numSubjects":"17"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"The study opened to participant enrollment on 05/14/2012 and closed to participant enrollment on 08/02/2016."}